金凯生科:9月22日召开董事会会议
Group 1 - The core point of the article is that Jinkai Biotechnology (SZ 301509) held its 9th meeting of the 2nd Board of Directors on September 22, 2025, to discuss the adjustment of the Audit Committee members [1] - For the fiscal year 2024, Jinkai Biotechnology's revenue composition is as follows: CDMO accounts for 98.68%, trade and others account for 0.82%, and technical services account for 0.51% [1] - As of the report date, Jinkai Biotechnology has a market capitalization of 4.4 billion yuan [1]